Cancer
Malignant Nasopharyngeal Neoplasm
CI-CAN-00005902Explore in graph →
Top-level261 active trials1 approved drugs
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005902Explore in graph →
Clinical trials
771 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (43)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05099978 | Asian Multicenter Prospective Study of ctDNA Sequencing(A-TRAIN) | unknown | — | 506 | National Cancer Center, JapanOTHER_GOV | 8 | Sep 4, 2024 | clinicaltrials |
| NCT06170021 | Occurrence of Radiation-induced Otitis Media in Nasopharyngeal Carcinoma Patients After Intensity Modulated Radiotherapy | unknown | — | 215 | Sun Yat-sen UniversityOTHER | 1 | Aug 6, 2024 |
| clinicaltrials |
| NCT05638269 | A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China | unknown | — | 12,000 | Zhujiang HospitalOTHER | 1 | Jul 29, 2024 | clinicaltrials |
| NCT06523933 | Distribution of Bacteria in OME After Radiotherapy For NPC. | unknown | — | 234 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT06486220 | PFLL Combined With PD-1 Antibody With or Without FMT for Oligometastatic NPC,a Phase III ,Open, Randomized Clinical Trial. | unknown | Phase 3 | 96 | Yun-fei XiaOTHER | 0 | Jul 3, 2024 | clinicaltrials |
| NCT06480903 | Exploratory Study of EBV DNA Titre Clearance Whilst on Proton Beam Therapy(ClearED) | unknown | — | 10 | The Christie NHS Foundation TrustOTHER | 0 | Jun 28, 2024 | clinicaltrials |
| NCT06472024 | Assessing Manual Acupuncture's Impact on Mucositis From Nasopharynx Cancer Radiotherapy: A Visual Analogue Scale (VAS) and Quality of Life Study | unknown | N/A | 30 | Indonesia UniversityOTHER | 0 | Jun 26, 2024 | clinicaltrials |
| NCT06442709 | Combined Anti-IL6R and Anticoagulation Therapy in Advanced NPC Patients | unknown | N/A | 100 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT05955105 | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 200 | Innolake BiopharmINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT04557020 | Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC | unknown | Phase 3 | 200 | Jiangxi Provincial Cancer HospitalOTHER | 1 | May 1, 2024 | clinicaltrials |
| NCT05858385 | Predictive Study on Acute Radiation Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients | unknown | — | 700 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT06364826 | Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma | unknown | Phase 2 | 60 | Zhejiang Cancer HospitalOTHER | 0 | Apr 15, 2024 | clinicaltrials |
| NCT06268600 | The Protection of Thyroid Function in IMRT for Nasopharyngeal Carcinoma | unknown | N/A | 320 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT04830267 | The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC | unknown | Phase 2 | 39 | Chongqing University Cancer HospitalOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT06097793 | KSD-101 Therapy for EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial | unknown | Early Phase 1 | 12 | Kousai Bio Co., Ltd.OTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06259721 | Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 22 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT05011227 | Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma | unknown | Phase 2 | 100 | Eye & ENT Hospital of Fudan UniversityOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT05893810 | Bacterial Decolonization to Prevent Radiation-induced Oral Mucositis | unknown | Phase 3 | 176 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05385926 | Combining RT With Immunotherapy and Chemotherapy in Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 34 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT03708822 | Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 48 | Sun Yat-sen UniversityOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT06032767 | Prospective Observational Study to Predict Severe Oral Mucositis Associated With Chemoradiotherapy in Nasopharyngeal Carcinoma Based on Deep Learning | unknown | — | 480 | Sun Yat-sen UniversityOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT06156878 | PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy | unknown | Phase 2 | 41 | Fudan UniversityOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT05576272 | A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma | unknown | Phase 2 / Phase 3 | 460 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 22, 2023 | clinicaltrials |
| NCT06136962 | Nasopharyngeal Carcinoma Treated With Reduced Volume Intensity Modulated Radiation Therapy:10-Year Outcome and Late Toxicity, Quality of Life | unknown | — | 500 | Fujian Cancer HospitalOTHER_GOV | 1 | Nov 18, 2023 | clinicaltrials |
| NCT06129201 | Development of a Machine Learning Model for Nasopharyngeal Carcinoma Screening Based on Tongue Imaging | unknown | — | 5,000 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT05202626 | Detection and Biopsy Guidance of Nasopharyngeal Carcinoma Based on Artificial Intelligence and Endoscopic Images | unknown | — | 100 | Chinese Academy of SciencesOTHER_GOV | 1 | Oct 17, 2023 | clinicaltrials |
| NCT05626829 | Tranilast as a Radiosensitizer in Reradiation of Nasopharyngeal Carcinoma | unknown | Phase 2 | 18 | Jian GuanOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT05520814 | PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II Trial | unknown | Phase 2 | 50 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT04593186 | Magnifying NBI for Occult NPC | unknown | N/A | 246 | Chinese University of Hong KongOTHER | 1 | Sep 7, 2023 | clinicaltrials |
| NCT05949749 | A Retrospective Study Reveals the Relationship Between gp42-IgG Epitopes and EBV-associated NPC | unknown | — | 1,000 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT05981157 | Anrotinib and Tirelizumab in First-line Treatment of RM-NPC | unknown | Phase 2 | 27 | Zhongshan People's Hospital, Guangdong, ChinaOTHER | 1 | Aug 8, 2023 | clinicaltrials |
| NCT02501993 | Nasopharyngeal Carcinoma Screening in Zhongshan City | unknown | — | 25,000 | Zhongshan People's Hospital, Guangdong, ChinaOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT04522050 | Gemcitabine-based Induction Chemotherapy Combined With Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma | unknown | Phase 1 | 65 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Jul 12, 2023 | clinicaltrials |
| NCT03925090 | Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients | unknown | Phase 2 | 150 | Sun Yat-sen UniversityOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT04850235 | Nab-paclitaxel Based TPX Neoadjuvant Chemotherapy for NPC Patients: a Dose-escalation Study | unknown | Phase 1 | 36 | Sun Yat-sen UniversityOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05913414 | Iron Isomaltide for Iron-deficiency Anemia Patients With Locally Advanced Nasopharyngeal Carcinoma | unknown | Phase 2 | 120 | Sun Yat-sen UniversityOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03855020 | Serial Epstein-Barr Virus DNA Surveillance in Nasopharyngeal Carcinoma Patients | unknown | — | 1,000 | Sun Yat-sen UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT04072107 | EPstein-barr Virus DNA Response to Systemic Therapy for Treatment Adaptation in High Risk NPC (EP-STAR)(EP-STAR) | unknown | Phase 2 | 110 | Sun Yat-sen UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT04221516 | Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma | unknown | Phase 2 | 52 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05898256 | Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma | unknown | Phase 1 / Phase 2 | 20 | Guangxi Medical UniversityOTHER | 0 | Jun 12, 2023 | clinicaltrials |
| NCT03321539 | Phase Ⅲ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal Carcinoma | unknown | Phase 3 | 216 | Sun Yat-sen UniversityOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT05771025 | Effect of Hepatectomy on the Prognosis of Patients With Nasopharyngeal Carcinoma Liver Metastases | unknown | N/A | 55 | Fudan UniversityOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT04586088 | Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure | unknown | Phase 2 | 58 | Sun Yat-sen UniversityOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT05229315 | PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal Carcinoma | unknown | Phase 2 | 45 | XIANG YANQUNOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT05790200 | Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma | unknown | Phase 2 | 30 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT05097209 | Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma | unknown | Phase 2 | 200 | Wei JiangOTHER | 1 | Mar 23, 2023 | clinicaltrials |
| NCT00941538 | Cluster Randomized Controlled Screening Trial for NPC(CRCSTNPC) | unknown | N/A | 87,600 | Sun Yat-sen UniversityOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT05724355 | CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC | unknown | Phase 2 | 32 | Sun Yat-sen UniversityOTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT05549466 | Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC | unknown | Phase 2 | 84 | Sun Yat-sen UniversityOTHER | 1 | Feb 8, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Sep 4, 2024source: clinicaltrials